S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94

Amarin (AMRN) Stock Forecast, Price & News

+0.24 (+19.20%)
(As of 05/13/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
11.54 million shs
Average Volume
4.18 million shs
Market Capitalization
$590.85 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter.

Amarin logo

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$583.19 million
Cash Flow
$0.07 per share
Book Value
$1.62 per share


Net Income
$7.73 million
Pretax Margin




Free Float
Market Cap
$590.85 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.03 out of 5 stars

Medical Sector

555th out of 1,403 stocks

Pharmaceutical Preparations Industry

254th out of 667 stocks

Analyst Opinion: 3.9Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Amarin (NASDAQ:AMRN) Frequently Asked Questions

Is Amarin a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last twelve months. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Amarin stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRN, but not buy additional shares or sell existing shares.
View analyst ratings for Amarin
or view top-rated stocks.

When is Amarin's next earnings date?

Amarin is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Amarin

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) posted its earnings results on Wednesday, May, 4th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.06. The biopharmaceutical company had revenue of $94.60 million for the quarter, compared to analyst estimates of $128.21 million. Amarin had a negative net margin of 4.15% and a negative trailing twelve-month return on equity of 1.31%. Amarin's revenue for the quarter was down 33.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.03 EPS.
View Amarin's earnings history

What price target have analysts set for AMRN?

6 analysts have issued 12 month price targets for Amarin's stock. Their forecasts range from $3.00 to $10.00. On average, they anticipate Amarin's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 252.3% from the stock's current price.
View analysts' price targets for Amarin
or view top-rated stocks among Wall Street analysts.

Who are Amarin's key executives?
Amarin's management team includes the following people:
  • Mr. Michael W. Kalb, CFO, Sr. VP & Assistant Sec. (Age 51, Pay $656.66k) (LinkedIn Profile)
  • Dr. Steven B. Ketchum Ph.D., Pres of R&D, Exec. VP and Chief Scientific Officer (Age 57, Pay $758.14k)
  • Mr. Aaron D. Berg, Exec. VP & Pres of U.S. (Age 59, Pay $656.09k)
  • Mr. Karim Mikhail, Pres, CEO & Director (Age 51)
  • Ms. Lisa M. DeFrancesco, Sr. VP of Corp. Affairs & Investor Relations (Age 42)
  • Mr. Jason M. Marks J.D., Exec. VP, Chief Legal and Compliance Officer & Corp. Sec. (Age 46)
  • Alina Kolomeyer, Director of Communications
  • Mr. Alan J. Wills B.A., BA (Zoology), M.B.A., MBA, Exec. VP of Corp. Bus. Devel. (Age 59)
  • Ms. Donna Pasek, Sr. VP of HR
  • Dr. Keith Wood, Head of R&D Operations
What is John Thero's approval rating as Amarin's CEO?

10 employees have rated Amarin CEO John Thero on Glassdoor.com. John Thero has an approval rating of 93% among Amarin's employees. This puts John Thero in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), (CGC), Square (SQ), Alibaba Group (BABA), Tesla (TSLA), Bank of America (BAC), Netflix (NFLX) and Novavax (NVAX).

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

Who are Amarin's major shareholders?

Amarin's stock is owned by a number of institutional and retail investors. Top institutional investors include Clearbridge Investments LLC (1.21%), Kynam Capital Management LP (0.58%), Group One Trading L.P. (0.00%), Resources Investment Advisors LLC. (0.20%), Cutter & CO Brokerage Inc. (0.18%) and Van ECK Associates Corp (0.15%). Company insiders that own Amarin stock include David M Stack, John F Thero, Joseph S Zakrzewski, Michael Wayne Kalb and Steven B Ketchum.
View institutional ownership trends for Amarin

Which institutional investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Group One Trading L.P., Edgestream Partners L.P., IMC Chicago LLC, Evanson Asset Management LLC, Handelsbanken Fonder AB, Briaud Financial Planning Inc, Simplex Trading LLC, and ProShare Advisors LLC.
View insider buying and selling activity for Amarin
or view top insider-selling stocks.

Which institutional investors are buying Amarin stock?

AMRN stock was bought by a variety of institutional investors in the last quarter, including Kynam Capital Management LP, Commonwealth Equity Services LLC, LCM Capital Management Inc, Cutter & CO Brokerage Inc., Advisor Group Holdings Inc., Clearbridge Investments LLC, Westside Investment Management Inc., and Resources Investment Advisors LLC.. Company insiders that have bought Amarin stock in the last two years include David M Stack, and Joseph S Zakrzewski.
View insider buying and selling activity for Amarin
or or view top insider-buying stocks.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $1.49.

How much money does Amarin make?

Amarin has a market capitalization of $590.85 million and generates $583.19 million in revenue each year. The biopharmaceutical company earns $7.73 million in net income (profit) each year or ($0.050010) on an earnings per share basis.

How many employees does Amarin have?

Amarin employs 560 workers across the globe.

Does Amarin have any subsidiaries?

The following companies are subsidiares of Amarin: Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharma Inc., Amarin Pharmaceuticals Ireland Limited, Amarin Switzerland GmbH, Amarin UK Limited, Ester Neurosciences, and Ester Neurosciences Limited.

When was Amarin founded?

Amarin was founded in 1991.

What is Amarin's official website?

The official website for Amarin is www.amarincorp.com.

How can I contact Amarin?

Amarin's mailing address is 77 Sir John Rogerson`s Quay Block C Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at (531) 669-9020 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.